Skip to Content
Merck
All Photos(1)

Documents

H2519

Sigma-Aldrich

Heparinase I from Flavobacterium heparinum

Lyophilized powder stabilized with approx. 25% bovine serum albumin, ≥200 units/mg protein (enzyme + BSA)

Synonym(s):

Heparin lyase I, Heparinase

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
Enzyme Commission number:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.54

conjugate

conjugate (Glucosaminoglycan)

Quality Level

form

lyophilized solid

specific activity

≥200 units/mg protein (enzyme + BSA)

mol wt

42.8 kDa

application(s)

diagnostic assay manufacturing

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

Application

Heparinase I from Flavobacterium heparinum has been used:
  • in the digestion of plasma samples
  • to study the effect of medium, washing and sonication on the infectivity of Chlamydia pneumonia
  • in enzymatic removal of heparan sulfate from the surface of human rhabdomyosarcoma cells

Biochem/physiol Actions

Heparinase I from Flavobacterium heparinum acts by cleaving the α-glycoside linkage at AT III binding site in heparin. This results in small oligosaccharide fragments . Heparinase I neutralizes the protein′s action of anticoagulation. Heparinase I possesses a half-life of 15-18 minutes.

Unit Definition

One unit (Sigma unit) will form 0.1 μmole of unsaturated uronic acid per hr at pH 7.5 at 25 °C. One International Unit (I.U.) is equivalent to approx. 600 Sigma units.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Resp. Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Methodological aspects affecting the infectivity of Chlamydia pneumoniae in cell cultures in vitro
Yan Y, et al.
Journal of Microbiological Methods, 61(1), 127-130 (2005)
M E Casey et al.
Anaesthesia, 68(1), 91-96 (2012-10-16)
Paediatric patients who require anticoagulation with therapeutic doses of low-molecular weight heparin are at risk of having a residual anticoagulant effect at the time of surgery, even if managed according to current peri-operative guidelines. Testing for residual effect is not
HeparinHeparin - A Century of Progress, 273-273 (2012)
Cardiopulmonary Bypass: Principles and Practice, 509-509 (2008)
Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum
Murphy MSQ, et al.
American Journal of Obstetrics and Gynecology, 213(3), 367-e1-367-e1 (2015)

Articles

Uncover more about glycosaminoglycans and proteoglycans including the structure of glycosaminoglycans (GAGs), the different types of GAGs, and their functions.

Uncover more about glycosaminoglycans and proteoglycans including the structure of glycosaminoglycans (GAGs), the different types of GAGs, and their functions.

Uncover more about glycosaminoglycans and proteoglycans including the structure of glycosaminoglycans (GAGs), the different types of GAGs, and their functions.

Uncover more about glycosaminoglycans and proteoglycans including the structure of glycosaminoglycans (GAGs), the different types of GAGs, and their functions.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service